Elsevier

European Journal of Medicinal Chemistry

Volume 102, 18 September 2015, Pages 363-374
European Journal of Medicinal Chemistry

Research paper
Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp)

https://doi.org/10.1016/j.ejmech.2015.07.016Get rights and content

Highlights

  • The small molecule compound 70 was identified based on the three mer peptide pENW (pGlu-Asn-Trp).

  • A series of Trp derivatives were synthesized and evaluated for antiplatelet aggregation activity.

  • The most potent compound 87 in our paper shows comparable ability as Tirofiban in inhibiting platelet aggregation.

  • Compound 87 has less bleeding risk compared with Tirofiban.

Abstract

pENW, a three mer peptide derived from Agkistrodon acutus Guenther venom, has been found to be an antagonist of the GPIIb/IIIa receptor and shows antiplatelet aggregation activity. Based on pENW and a GPIIb/IIIa inhibitor Tirofiban, a series of tryptophan derivatives were designed, synthesized and evaluated for their antiplatelet aggregation activity induced by ADP. The most potent compound 87 was also tested for the bleeding time and antithrombotic activity in vivo in comparison with Tirofiban. The results indicated that 87 shows similar antiplatelet aggregation activity as Tirofiban to the aggregation of platelet induced by all of the four agonists, but has lower bleeding risk than Tirofiban, representing a promising lead compound for further study.

Introduction

Aggregation of platelets is the leading cause of arterial thrombosis and hemostatis. Severe cardiovascular disorders, such as transient ischemic attack, myocardial infarction, and unstable angina pectoris have been reported to be related to uncontrolled platelet aggregation and platelet adhesion to the subendothelium of damaged blood vessels [1].

Several mechanisms have been found in the induction of the aggregation of platelets, including the stimulation by ADP, thrombin, collagen, TXA2 or sheer stress [2], [3], [4]. In response to these stimulations, GPIIb/IIIa, a heterodimeric membrane protein expressed on the surface of platelets, undergoes a substantial conformational change which enhances its binding affinity to fibrinogen, a multi-valent plasma protein. Binding of multiple GPIIb/IIIa molecules to a single molecule of fibrinogen is the key step for crosslinking of the platelets and thrombus formation (Fig. 1) [5], [6], [7], [8], [9], [10], therefore, development of small molecular compounds to inhibit the binding of fibrinogen to GPIIb/IIIa has been considered as an attractive strategy for suppressing aggregation of platelets and thrombus formation.

Three GPIIb/IIIa inhibitors have been approved to use in clinic, among them Abciximab is an antibody, while Eptifibatide and Tirofiban are peptidic mimetics mimicking tri-peptide Arg-Gly-Asp (RGD), the minimum binding epitope of fibrinogen to the GPIIb/IIIa receptor [11], [12], [13]. Currently, many RGD mimetics are in different stage of clinical trials as antithrombotic agents, however, most of them either fail to demonstrate sufficient efficacy or show severe side effects, such as thrombocytopenia and bleeding risk. Therefore, development of new antithrombotic drugs with improved efficacy and reduced side effects is urgently needed [14], [15], [16], [17], [18], [19], [20].

Recently, we found that pENW (Fig. 2), a three mer peptide derived from Agkistrodon acutus Guenther venom can inhibit platelet aggregation and thrombus formation in both arterial and venous thrombosis models [21]. Moreover, it could prolong the coagulation time in mice without extending the haemorrhage time. Because pENW inhibits platelet aggregation induced by all of the four agonists, we hypothesize that it may function by disturbing the interaction of GPIIb/IIIa with fibrinogen. Therefore, we tested its inhibition to GPIIb/IIIa receptor using fibrinogen/GPIIb/IIIa enzyme-linked immunosorbent assay (ELISA). In this assay, pENW shows an IC50 value of 12.5 μM, similar to a known GPIIb/IIIa receptor inhibitor, RGDS (IC50 = 5.1 μM) [22], [23], thus representing a promising lead compound. However, pENW has very short half-life, and its activity in anti-platelet aggregation is not very potent, therefore, in our present study, we performed extensive modifications to pENW with the purpose to improve the activity in anti-platelet aggregation and to reduce the bleeding risk.

Section snippets

Design and hit identification

Our previous study indicated that GPIIb/IIIa receptor is one of targets of pENW. Based upon the crystal structure of Tirofiban in complex with GPIIb/IIIa (PDB code: 2VDM), we have performed the docking study for pENW in binding to GPIIb/IIIa receptor using CDOCKER and the result is shown in Fig. 3. In the crystal structure, the 4-piperidyl group in Tirofiban has salt bridge interaction with the carboxyl group of the Asp224 residue in GPIIb subunit. The carboxyl group forms several hydrogen

Conclusion

In our previous work [22], [23], we have identified a three mer peptide pENW from Agkistrodon acutus Guenther venom as an effective antagonist of GPIIb/IIIa receptor. By comparing the binding model of pENW with GPIIb/IIIa receptor with the crystal structure of Tirofiban in complex with GPIIb/IIIa receptor, we found that the Trp moiety in pENW is the major portion for interacting with the GPIIb/IIIa receptor. Based upon this moiety, we designed and synthesized a series of Trp derivatives by

Chemistry

All reagents were from commercial sources. With tetramethylsilane (TMS) as internal standard, the 1H NMR and 13C NMR were recorded on Bruker AV-300 apparatus by using deuterated solvents. HR-MS was collected on Agilent technologies 6520 Accurate-Mass Q-TOF LC/MS instruments. Every targeted compound was purified via silica gel (60 Å, 70–230 mesh) column chromatography. Melting points were measured by XT-4 melting point apparatus.

Acknowledgments

This work was supported by the project 81273375 of National Natural Science Foundation of China, China Pharmaceutical University. The authors declare no other conflicts of interest.

References (25)

  • U. Trstenjak et al.

    Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

    Eur. J. Med. Chem.

    (2013)
  • A. Garg et al.

    Newer anti-platelet and anti-thrombotic drugs on the horizon

    Nat. J. Physio. Pharm. Pharmacol.

    (2013)
  • Cited by (5)

    • Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

      2022, European Journal of Medicinal Chemistry
      Citation Excerpt :

      The most active thioureas compounds 73a, 73b, 73c and 73d (IC50: 29.00–84.00 μM) compared to aspirin (IC50: 30.56 ± 0.40 μM) directly affected the formations of PGE2 and TXA2, reduced thromboxane B2 (TXB2) production and directly inhibited COX-1 to achieve antiplatelet effect in human thrombus model. In order to search for new platelet aggregation inhibitors, Xie et al. [86] designed and synthesized two series of 1, 4-benzodioxazine derivatives based on the previous antiplatelet drugs LX2421, which had effective antiplatelet activity and no risk of bleeding [87,88]. By introducing 1,4-bendioxazine to replace the indole structure in LX2421, new 1,4-bendioxazine derivatives were established as the platelet aggregation inhibitors (Fig. 52).

    • Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation

      2017, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Among them, LX2421 was the most potent compound which inhibits platelet aggregation induced by all of the four agonists (ADP, Thrombin, U46619 and Collagen). It has an IC50 value of 24.8 μM in an assay using ADP-induced rabbit platelet-rich plasma and shows moderate GPIIb/IIIa receptor inhibitory activity with an IC50 value of 5.4 μM, as potent as the known GPIIb/IIIa receptor antagonist, RGDs [23]. In addition, LX2421 has much lower bleeding risk than Tirofiban and remarkable antithrombotic activity in arterial and venous thrombosis models in rats.

    View full text